National Coverage Analysis (NCA) Tracking Sheet

Electrodiagnostic Sensory Nerve Conduction Threshold

CAG-00106R

Issue

The Centers for Medicare and Medicaid Services (CMS) has been asked to reconsider the national non-coverage policy on Sensory Nerve Conduction Threshold (sNCT) testing which it announced in a February 14, 2002 decision memorandum. This device is a noninvasive test performed to evaluate and document a variety of sensory neuropathological conditions.

Benefit Category

Diagnostic Tests (other)

Requestor Information

Requestor Name Requestor Letter
Neurotron, Incorporated View Letter
N/A

Important Dates

Formal Request Accepted and Review Initiated
11/01/2002
Expected NCA Completion Date
02/21/2003
Public Comment Period
12/02/2002 - 01/02/2003
Proposed Decision Memo Due Date
Proposed Decision Memo Released
Proposed Decision Memo Public Comment Period
Decision Memo Released
07/08/2003

Contacts

Lead Analysts
Lorrie Ballantine
Lead Medical Officers
James Sorace, MD
Ronald Dei Cas, MD

Medicare Benefit Category Determination Date

Actions Taken

November 1, 2002

Formal request for reconsideration accepted by CMS.

January 15, 2003

Neuro-Dx Associates, Inc., the manufacturer of Medi-Dx 7000, a voltage-actuated sensory nerve conduction threshold testing device (v-sNCT), has stated that their device is substantially different than sNCT/CPT. According to the manufacturer their device measures voltage input, not current output. We will address this question as part of this review.  To accommodate this part of the review and provide for comments on this issue, we will extend the deadline to February 21, 2003.

July 8, 2003